RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.

Icosavax, a US-based vaccine developer exploiting research from University of Washington (UW) completed a $100m series B round yesterday led by investment manager RA Capital Management. Pharmaceutical firm Sanofi’s strategic investment arm, Sanofi Ventures, also took part, as did Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Open Philanthropy and…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.